Showing results (701-710 of 1,188) with videos related to
Sort By:
Pageof 119
Leukemia & Lymphoma|October 4, 2017
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage settingPrajwal Boddu, Abdul Rashid Shah, Gautam Borthakur, et al.Leukemia & Lymphoma|July 28, 2010
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapyQaiser Bashir, Marcos J De Lima, John D McMannis, et al.Neurosurgery|July 25, 2022
Intracranial Pressure Monitoring in Patients With Severe Traumatic Brain Injury: Extension of the Recommendations and the Effect on Outcome by Propensity Score MatchingAna M Castaño-Leon, Pedro A Gomez, Luís Jimenez-Roldan, et al.Blood Neoplasia|June 2, 2025
Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMMLSamuel Urrutia, Prithviraj Bose, Yesid Alvarado, et al.Leukemia & Lymphoma|December 28, 2020
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndromeBeata Holkova, Danielle Shafer, Victor Yazbeck, et al.Revista De Neurologia|June 11, 2014
[Characterisation of factors associated with carotid stenosis in a population at high risk]Erwin Chiquete, Benjamín Torres-Octavo, Vanessa Cano-Nigenda, et al.British Journal of Haematology|November 10, 2023
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agentsGuillermo Montalban-Bravo, Elias Jabbour, Gautam Borthakur, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring systemJulie Schanz, Christian Steidl, Christa Fonatsch, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.British Journal of Haematology|October 15, 2014
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosisNaval Daver, Hagop Kantarjian, Guido Marcucci, et al.Pageof 119